18 recruiting, 11 completed, 7 active not recruiting, 4 terminated. 21 Phase 2, 13 Phase 1, 6 Phase 3, 2 Phase 4, 1 Early Phase 1.
Follow asciminib: new trials by email Literature Review of asciminib trials Research Report on asciminib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Asciminib, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2026-12-17 | 2026-10-19 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-11-30 | 2026-10-13 |
| Asciminib With or Without Sildenafil for Brain Tumors Asciminib, Sildenafil, Surgical resection or biopsy - Brain Tumor | Early Phase 1 | Not yet recruiting | Washington University School of Medicine | 12 | 2026-10-31 | 2026-09-11 |
| Asciminib in HER2+ Breast Cancer Brain Metastases Asciminib and Trastuzumab - HER2+ Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Duke University | 42 | 2026-07-07 | 2026-07-22 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-10-15 |
| Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations asciminib 200 mg BID - Chronic Myeloid Leukemia (CML) | Phase 2 | Active not recruiting | Thomas Ernst, PD Dr. med. | 50 | 2026-06-22 | 2026-08-27 |
| Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP Asciminib single agent - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-04-28 | 2026-10-15 |
| Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL Asciminib - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 36 | 2026-01-21 | 2026-03-27 |
| A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy TKIs - Chronic Myelogenous Leukemia - Chronic Phase | Recruiting | Novartis Pharmaceuticals | 1000 | 2025-12-17 | 2026-07-20 | |
| PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Asciminib, Nilotinib - CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 160 | 2025-06-26 | 2025-07-08 |
| RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL) asciminib - Chronic Myelogenous Leukemia in Chronic Phase | Recruiting | Novartis Pharmaceuticals | 40 | 2025-03-24 | 2025-12-23 | |
| Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. ABL001/Asciminib - Chronic Myeloid Leukemia (CML) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 20 | 2025-02-18 | 2026-04-21 |
| Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia Asciminib - Malignant Solid Tumors | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2025-02-14 | 2026-10-13 |
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation Asciminib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase | Phase 4 | Completed | Novartis Pharmaceuticals | 85 | 2024-11-28 | 2026-06-08 |
| Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Blinatumomab, Asciminib - Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-08-05 | 2026-10-13 |
| A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia Asciminib - Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Recruiting | Korean Society of Hematology | 69 | 2024-03-11 | 2026-04-02 |
| Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France Asciminib - Chronic Myeloid Leukemia | Active not recruiting | Novartis Pharmaceuticals | 201 | 2024-03-06 | 2026-05-29 | |
| Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Asciminib - Chronic Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 150 | 2024-01-31 | 2026-10-13 |
| Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML Asciminib, Imatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive | Phase 3 | Terminated | Sarit Assouline | 8 | 2023-11-01 | 2026-05-29 |
| Asciminib RMP Study Asciminib - Chronic Myeloid Leukemia | Recruiting | Novartis Pharmaceuticals | 600 | 2023-07-19 | 2026-04-20 |
Showing 20 of 43. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (25) · Leukemia, Myeloid, Chronic-Phase (8) · Bronchiolitis Obliterans Syndrome (3) · Leukemia (3) · Leukemia, Myeloid (3) · Myeloproliferative Disorders (2) · Philadelphia Chromosome (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Blast Crisis (1) · Brain Neoplasms (1) · Burkitt Lymphoma (1) · Hematologic Diseases (1) · Recurrence (1) · Renal Insufficiency (1)
Novartis Pharmaceuticals (24) · M.D. Anderson Cancer Center (5) · ABL Bio, Inc. (1) · City of Hope Medical Center (1) · Duke University (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Handok Inc. (1) · Korean Society of Hematology (1) · Marlise Luskin, MD (1) · Medical College of Wisconsin (1) · Sarit Assouline (1) · Thomas Ernst, PD Dr. med. (1) · University of Alabama at Birmingham (1) · University of Jena (1)
United States (24) · South Korea (14) · Germany (12) · France (11) · Italy (10) · Canada (8) · Spain (8) · Japan (7) · Netherlands (6) · United Kingdom (6) · Australia (5) · Bulgaria (5) · China (5) · Czechia (5) · Hungary (5)
Ehab Atallah, MD (1) · Elias Jabbour, MD (1) · Eric Thompson, M.D. (1) · Fadi Haddad, MD (1) · Fausto Castagnetti (1) · Ghayas C Issa (1) · Ghayas Issa, MD (1) · Hawk Kim (1) · Ibrahim Aldoss (1) · Jorge S Cortes, MD (1) · Marlise R. Luskin, MD (1) · Michael J. Mauro, MD (1) · Nicholas Short, MD (1)
PMID 34115385, PMID 35764773, PMID 31826340, PMID 33383646, PMID 34407542, PMID 36168187, PMID 36524980, PMID 37431294, PMID 38755421, PMID 38820078, PMID 39374521, PMID 39387441, PMID 39696526, PMID 40334072, PMID 41397287, PMID 41671463, PMID 42339511
2023 (3), 2025 (3), 2018 (2), 2016 (1), P30CA033572 (1)